Key takeaway
In an online survey of 418 people with diabetes, 83.9% saw wearables as useful for monitoring glucose and activity, but 79.7% worried about data privacy, 77.0% about cost and 75.1% about usability; 81.9% would adopt AI-integrated devices if their healthcare provider recommended them. These are self-reported attitudes from a self-selected online sample, not evidence that the devices improve diabetes control.
Study design
Cross-sectional study
Reading basis
Published abstract
Reading focus
Association & confounding
The research question
AI-enabled wearables can monitor diabetes in real time, but they only help if people accept and use them. The authors wanted to know what people with diabetes think about these devices: their perceived benefits, obstacles and the features they want, in order to guide design and care.
Who and how
Cross-sectional online survey of 418 people with diabetes, recruited through online platforms and diabetes groups. A structured questionnaire used Likert-scale items, multiple-choice questions and open-ended responses. Quantitative data were analyzed with descriptive statistics and open-ended answers with thematic analysis. The abstract does not report the type of diabetes, age, country or response rate.
What it found
The authors’ reported results. Read each estimate with its population and uncertainty.
- 183.9% acknowledged the usefulness of wearable devices for monitoring glucose and physical activity.
- 2The main perceived advantages were better adherence to medication (81.9%) and more confidence in managing diabetes (82.1%).
- 3The main barriers were data privacy concerns (79.7%), cost (77.0%) and usability challenges (75.1%).
- 4Open-ended answers asked for actionable feedback, integration with healthcare providers and better usability. 81.9% said they would adopt AI-integrated wearables if recommended by healthcare providers.
Limits & uncertainty
- 1Participants were recruited online and through diabetes groups, so they are probably more comfortable with technology than people with diabetes in general.
- 2The percentages are self-reported perceptions of benefit, not measured changes in medication adherence or glucose control.
- 3The abstract gives no breakdown by type of diabetes, age or country, and no confidence intervals.
- 4This reading is based on the abstract only, and the authors use descriptive statistics, so no comparison between groups can be drawn.
What to take from it
The survey suggests people with diabetes are open to AI-enabled wearables, especially with clinician backing, and that privacy, cost and ease of use are the sticking points to check before buying one. It does not show these devices improve outcomes. Choices about glucose monitoring and treatment belong with a diabetes care team.
Reading your own data
If you use a CGM or activity tracker, check what data the app shares and with whom, and whether your care team can see it. Compare readings from the same device, and look at patterns over days and weeks rather than a single value.
How to read this evidence
Measurements are taken in the same period. Direction and causation usually cannot be determined; symptoms can change behaviour as well as the reverse.
Authors’ structured abstract English
The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.
Abstract
Wearable devices that incorporate artificial intelligence (AI) have become effective instruments for managing diabetes through real-time monitoring, improved adherence, and increased person with diabetes engagement. Person with diabetes perceptions, adoption barriers, and preferences critically impact the effectiveness and widespread utilisation of these technologies.
Aim
The aim of study was to investigate the perceptions of people with diabetes regarding wearable devices, emphasising their perceived advantages, challenges, and potential role in facilitating diabetes self-management.
Methods
A cross-sectional study involving 418 people with diabetes was conducted, with participants recruited via online platforms and people with diabetes groups. Data were gathered through a structured questionnaire that included Likert-scale items, multiple-choice questions, and open-ended responses. Descriptive statistics were employed to analyse quantitative data, whereas qualitative responses underwent thematic analysis to discern key trends.
Results
Participants demonstrated significant awareness of the primary functions of wearable devices, with 83.9% acknowledging their utility in monitoring glucose levels and physical activity. The primary advantages comprised increased adherence to medication regimens (81.9%) and heightened confidence in diabetes management (82.1%). Significant barriers were identified, including data privacy concerns (79.7%), cost issues (77.0%), and usability challenges (75.1%). Thematic analysis of open-ended responses indicated a demand for features including actionable feedback, integration with healthcare providers, and enhanced usability. Despite these challenges, 81.9% of participants indicated a willingness to adopt AI-integrated wearable devices if recommended by healthcare providers.
Conclusion
The findings indicate that people with diabetes regard wearable devices as effective instruments for managing their condition, especially in terms of real-time monitoring and adherence support. Concerns regarding privacy, cost, and device usability must be addressed to enhance adoption rates. These insights can inform the development of patient-centered wearable devices and guide healthcare strategies for the effective integration of these technologies into diabetes care.
Sources & attribution
Perspectives of people with diabetes on AI-integrated wearable devices: perceived benefits, barriers, and opportunities for self-management.
Alzghaibi H.
Frontiers in medicine · 2025-04-23
DOI: 10.3389/fmed.2025.1563003 ↗PubMed · 40337275 ↗Europe PMC · Recorded licence: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
MoveVitals editorial interpretation · educational content · no individual clinical review recorded
Sources checked 2026-11-01
Practical guides
Read in context
Activity–stroke and heart attack curves differ by accelerometer processing method
Among 90,237 UK Biobank adults free of cardiovascular disease at baseline, followed until December 2022 for 1,298 strokes and 2,031 myocardial infarctions, the shape of the link between moderate-vigorous physical activity (MVPA) and each outcome depended on how the accelerometer data were processed. For stroke, hazard fell in a straight line only with the machine-learning metric; for myocardial infarction, two metrics gave a curved decline and activity counts a straight one. The abstract gives no hazard ratios, so it shows that methods disagree, not which one is right, and the findings are observational associations.
Preventive Medicine
Smartwatch data as forensic evidence: heart rate is best validated, the rest uneven
A systematic review and meta-analysis of studies on smartwatches from four major brands, framed around digital forensics, found that heart rate was both the most studied and the most accurate measure. Step count, distance, energy expenditure, activity classification and sleep were less consistently validated, and results varied by brand, protocol and reporting. The abstract gives no pooled numbers, and most studies were run in healthy people in laboratories, so it cannot say how a particular watch performs for a particular person in daily life.
Forensic Science International
Activity trackers: about 1,800 more steps a day, but small effects on other outcomes
An umbrella review of 39 systematic reviews and meta-analyses, covering 163,992 participants, found that activity trackers were associated with more physical activity (SMD 0.3–0.6), equating to about 1,800 extra steps and 40 minutes more walking per day, and with a bodyweight reduction of about 1 kg. Effects on blood pressure, cholesterol, glycosylated haemoglobin, quality of life and pain were typically small and often non-significant. The abstract does not say what else came with the trackers in these programs or how much the reviews overlap, so the gains cannot be credited to the device alone.
The Lancet Digital Health
Seven sleep trackers: good at spotting sleep, weak on wake and sleep stages
In a sleep laboratory, 34 healthy young adults wore a subset of seven consumer sleep trackers for three nights. Against polysomnography every device detected sleep very well (sensitivity 0.93 or higher) but caught wake poorly (specificity 0.18–0.54), and five of the seven matched or beat research actigraphy (specificity 0.39). Sleep-stage estimates were inconsistent, and the participants were healthy adults aged 18 to 35 in a fixed 8-hour bed window, with each device tested in only 11 to 20 of them, so the results say little about people with sleep problems.
Sleep

